Concurrent chemoradiotherapy with paclitaxel and cisplatin for adenocarcinoma of the cervix.
It is unclear whether cisplatin-based concurrent chemoradiotherapy (CCRT) has the same effect on adenocarcinoma as on squamous cell carcinoma. We retrospectively analyzed data for 32 patients with stage IIB-IVA cervical adenocarcinoma who were treated with radiotherapy (RT) or CCRT. Fourteen patients were treated with RT, 8 with CCRT using cisplatin alone (CCRT-P), and 10 with CCRT using cisplatin plus paclitaxel (CCRT-TP). Complete response was achieved in 7/14 patients in the RT group, 4/8 patients in the CCRT-P group, and 9/10 patients in the CCRT-TP group. Ten out of the 14 patients in the RT, 7/8 patients in the CCRT-P, and 2/10 patients in the CCRT-TP groups experienced locoregional recurrence. The 5-year overall survival rate in the RT, CCRT-P, and CCRT-TP groups was 7.1%, 25.0%, and 74.1%, respectively (p=0.0094). The present study demonstrated that CCRT-TP achieved much better local control for adenocarcinoma of the cervix, leading to a decrease in locoregional recurrence.